Chennai: Paraguay hopes to partner with India on a diverse range of industries including natural resources, agriculture and education said the Ambassador of Paraguay to India, Genaro Vicente Pappalardo.
Addressing a meeting organised by the Southern India Chamber of Commerce and Industry, he said the cost of living in Asuncion, the country’s capital, is the lowest among capital cities in the world. Paraguay has also business-friendly policies and easy to settle in.
Education is an important area with its young population going out to study in Europe and the US. Also in the last three decades, Paraguay has set up more than 50 universities.
R. Thandavan, Vice-Chancellor, University of Madras, said the institution set up in 1857 has tie-ups with over 200 universities across the globe and is keen to partner with its counterparts in Paraguay.
Student and faculty exchange and research collaborations could be explored, he said
Success in my Habit
Showing posts with label INDIAN. Show all posts
Showing posts with label INDIAN. Show all posts
Friday, May 17, 2013
Thursday, June 21, 2012
Indian drug outlook favourable: ICRA & Moody's
Ahmedabad: Outlook on the Indian pharmaceutical industry remains favourable, says ICRA & Moody report released on Wednesday. Domestic formulation market grew by 13-16% per annum in last five years.
According to the report, domestic formulation market size stood at Rs 58,300 crore, ranked third in terms of volume and tenth in terms of value, globally. The domestic growth was driven mainly by expansion in volumes and new introductions. Lifestyle-related disorders are driving growth at faster pace in chronic segments along with increasing healthcare spending.
Product patent regime was not a major constraint currently, as companies have however, not been affected as existing products continue to exhibit extended life cycle and companies continue to launch novel combinations to support growth. Lastly, limited number of products have been launched under patent protection in India. Compulsory licensing route also provides faster access to market
However, domestic companies will face challenges and competition from regulatory driven price cuts, smaller players aggression and MNCs generic majors are setting an eye on the $12-13 billion market growing at 14-15% per annum.
From 2011, trends are changing, MNCs has stepped up their focus on the Indian market as they are pursuing a comprehensive strategy. They are focusing on chronics, branded generics and launching patented products from portfolio of parent companies. Expanding their field force and focusing on Tier -II as well as Tier - IV towns. Domestic market grew at 15%, while MNC pharma revenue grew at 18.7%.
For Indian companies eyeing US generics market, seven out of the top 20 innovators products will face generic competition in 2012 with $35 billion in value. Key products losing patent protections in 2012 include - Lexapro, Geodon, Seroquel, Plavix, Tricor, Singulair and Actos. Branded drugs worth $70 billion are likely to loose patent protections between 2013-17, the report indicates.
According to the report, domestic formulation market size stood at Rs 58,300 crore, ranked third in terms of volume and tenth in terms of value, globally. The domestic growth was driven mainly by expansion in volumes and new introductions. Lifestyle-related disorders are driving growth at faster pace in chronic segments along with increasing healthcare spending.
Product patent regime was not a major constraint currently, as companies have however, not been affected as existing products continue to exhibit extended life cycle and companies continue to launch novel combinations to support growth. Lastly, limited number of products have been launched under patent protection in India. Compulsory licensing route also provides faster access to market
However, domestic companies will face challenges and competition from regulatory driven price cuts, smaller players aggression and MNCs generic majors are setting an eye on the $12-13 billion market growing at 14-15% per annum.
From 2011, trends are changing, MNCs has stepped up their focus on the Indian market as they are pursuing a comprehensive strategy. They are focusing on chronics, branded generics and launching patented products from portfolio of parent companies. Expanding their field force and focusing on Tier -II as well as Tier - IV towns. Domestic market grew at 15%, while MNC pharma revenue grew at 18.7%.
For Indian companies eyeing US generics market, seven out of the top 20 innovators products will face generic competition in 2012 with $35 billion in value. Key products losing patent protections in 2012 include - Lexapro, Geodon, Seroquel, Plavix, Tricor, Singulair and Actos. Branded drugs worth $70 billion are likely to loose patent protections between 2013-17, the report indicates.
Wednesday, March 16, 2011
Toyota Motors to invest in Rs 300 cr to enhance capacity of its Indian subsidiary
NEW DELHI: Toyota Motors Corp (TMC) will invest Rs 300 crore to enhance capacity of its Indian subsidiary by 60,000 units in the next one year.
Toyota Kirloskar Motors (TKM), the local subsidiary of the Japanese company, will take the cumulative capacity of its two plants in Bangalore to 2.1 lakh units to meet rising demand from the local market.
"We have plans to grow gradually as demand will justify our capacity additions. The major expansion will be for our Etios sedan and its yet-to-be-launched hatchback model Etios Liva. In case, the local demand outstrips our capacity projections in the domestic market, we may accelerate our expansion for the Indian customers," TKM's MD Hiroshi Nakagawa said.
These expansion plans comes after the parent TMC plans to have larger focus on emerging market including Asia and projects a larger chunk of sales from such markets. The world's largest car maker, by sales, Toyota is looking at 50% of its future sales coming from Brazil, Russia, China and India (commonly referred as BRIC) and other emerging markets.
"Fortunately we have a huge booking backlog for Etios and other cars that stretches up to six months in different cities and towns of India. But even after successive expansions in place to make deliveries faster to customers, we have not able able to bridge the demand-supply gap. We will expand in stage to narrow down the gap in next few months," Nakagawa added.
Toyota's India sales grew 31% to 74,362 units in the April-February months, which gives it around 3.5% market share of the 2.2 million Indian passenger car sold in the same period.
The company also plans to start exporting cars from India, primarily Etios to similar emerging market in near future, though is has not frozen any exact countries for shipment. Currently its entire production is targets Indian customers only.
Toyota Kirloskar Motors (TKM), the local subsidiary of the Japanese company, will take the cumulative capacity of its two plants in Bangalore to 2.1 lakh units to meet rising demand from the local market.
"We have plans to grow gradually as demand will justify our capacity additions. The major expansion will be for our Etios sedan and its yet-to-be-launched hatchback model Etios Liva. In case, the local demand outstrips our capacity projections in the domestic market, we may accelerate our expansion for the Indian customers," TKM's MD Hiroshi Nakagawa said.
These expansion plans comes after the parent TMC plans to have larger focus on emerging market including Asia and projects a larger chunk of sales from such markets. The world's largest car maker, by sales, Toyota is looking at 50% of its future sales coming from Brazil, Russia, China and India (commonly referred as BRIC) and other emerging markets.
"Fortunately we have a huge booking backlog for Etios and other cars that stretches up to six months in different cities and towns of India. But even after successive expansions in place to make deliveries faster to customers, we have not able able to bridge the demand-supply gap. We will expand in stage to narrow down the gap in next few months," Nakagawa added.
Toyota's India sales grew 31% to 74,362 units in the April-February months, which gives it around 3.5% market share of the 2.2 million Indian passenger car sold in the same period.
The company also plans to start exporting cars from India, primarily Etios to similar emerging market in near future, though is has not frozen any exact countries for shipment. Currently its entire production is targets Indian customers only.
Monday, February 21, 2011
Indian doctor awarded for community service
New York: Dr Shuvendu Sen, MD has recently received the 2011 Oscar Edwards E. Award from American College of Physicians (ACP) in North Carolina for outstanding contributions to Community. Presently, attending Physician of Internal Medicine at Betsy Johnson Hospital, North Carolina, Dr Sen has been instrumental in the implementation of a voluntary organization called Project Access in his County for the treatment of uninsured and low income population.
Sen was awarded at the Washington Inn, Duke University, North Carolina by the ACP Governor Byron Hoffman Jr, MD on Jan 28th,2011. He is currently serving as the Chief Editor of a medical text book titled Principles of Clinical Medicine, to be published in 2012.
Sen was awarded at the Washington Inn, Duke University, North Carolina by the ACP Governor Byron Hoffman Jr, MD on Jan 28th,2011. He is currently serving as the Chief Editor of a medical text book titled Principles of Clinical Medicine, to be published in 2012.
Subscribe to:
Posts (Atom)